and its metabolites regulate vascular tone; however, the sources of the ATP released in vascular beds are ill defined. As such, we tested the hypothesis that all limbs of an extracellular purinergic signaling system are present in vascular endothelial cells: ATP release, ATP receptors, and ATP receptortriggered signal transduction. Primary cultures of human endothelial cells derived from multiple blood vessels were grown as monolayers and studied using a bioluminescence detection assay for ATP released into the medium. ATP is released constitutively and exclusively across the apical membrane under basal conditions. Hypotonic challenge or the calcium agonists ionomycin and thapsigargin stimulate ATP release in a reversible and regulated manner. To assess expression of P2X purinergic receptor channel subtypes (P2XRs), we performed degenerate RT-PCR, sequencing of the degenerate P2XR product, and immunoblotting with P2XR subtype-specific antibodies. Results revealed that P2X4 and P2X5 are expressed abundantly by endothelial cell primary cultures derived from multiple blood vessels. Together, these results suggest that components of an autocrine purinergic signaling loop exist in the endothelial cell microvasculature that may allow for "self-regulation" of endothelial cell function and modulation of vascular tone. purinergic receptors; cytosolic calcium; ectoadenosinetriphosphatases; exocytosis; nitric oxide PURINERGIC SIGNALING REGULATES circulatory function (4, 15, 20, 21, 27) . Nowhere has this signaling been studied more extensively in the cardiovascular system than in adenosine modulation of cardiac function (2, 12, 17). G protein-coupled P2Y purinergic receptors are expressed on vascular smooth muscle cells, platelets, and endothelial cells (4, 15, 20, 21, 27, 29, 33) . In endothelial cells derived from multiple vessels, extensive study has shown the molecular and functional expression of P2Y 1 and P2Y 2 receptors (4, 15, 20, 21, 27, 29, 33) . A specific isoform of the P2X purinergic receptor channel family, P2X 1 , a protein that binds ATP in its extracellular domain and also acts as a Ca 2ϩ -permeable, nonselective cation channel, was cloned from vascular smooth muscle (32). Expression of P2X 1 has been documented in human umbilical and human renal vasculature (3, 9). More recently, expression of P2X 4 as well as weaker expression of other P2XR subtypes was documented by Northern blot analysis and competitive, specific RT-PCR in endothelial cells (35). Immunoblotting for P2XR proteins as well as comprehensive studies of ATP release from these same human vascular endothelial cells was not performed (35). Only a few additional studies have hinted at P2X receptor expression in vascular cells (16, 23) .
PURINERGIC SIGNALING REGULATES circulatory function (4, 15, 20, 21, 27) . Nowhere has this signaling been studied more extensively in the cardiovascular system than in adenosine modulation of cardiac function (2, 12, 17) . G protein-coupled P2Y purinergic receptors are expressed on vascular smooth muscle cells, platelets, and endothelial cells (4, 15, 20, 21, 27, 29, 33) . In endothelial cells derived from multiple vessels, extensive study has shown the molecular and functional expression of P2Y 1 and P2Y 2 receptors (4, 15, 20, 21, 27, 29, 33) . A specific isoform of the P2X purinergic receptor channel family, P2X 1 , a protein that binds ATP in its extracellular domain and also acts as a Ca 2ϩ -permeable, nonselective cation channel, was cloned from vascular smooth muscle (32) . Expression of P2X 1 has been documented in human umbilical and human renal vasculature (3, 9) . More recently, expression of P2X 4 as well as weaker expression of other P2XR subtypes was documented by Northern blot analysis and competitive, specific RT-PCR in endothelial cells (35) . Immunoblotting for P2XR proteins as well as comprehensive studies of ATP release from these same human vascular endothelial cells was not performed (35) . Only a few additional studies have hinted at P2X receptor expression in vascular cells (16, 23) .
Despite the fact that, for decades, it has been postulated that ATP and adenosine act locally within vascular beds to regulate tissue vascular tone, the sources of ATP within the vasculature are largely unknown. Moreover, P2XR expression has not been characterized fully in vasculature. In particular, ATP release by endothelial cells is ill defined. As such, we tested the hypothesis that the endothelium, the layer of cells that lines all blood vessels, may provide a source of a physiological purinergic agonist, ATP, locally within vascular beds. Moreover, we tested the hypothesis that endothelial cells, in addition to vascular smooth muscle cells, also may express multiple subtypes of the emerging P2XR family to bind this released ATP and transduce this extracellular ATP signal in an autocrine or paracrine manner. Results demonstrate that human endothelial cell monolayers release ATP exclusively into the apical medium in a regulated manner and that endothelial cells express multiple P2XR subtypes.
MATERIALS AND METHODS
Endothelial cell primary culture. Human endothelial cells were isolated into primary culture from different blood vessels by Clonetics and purchased as proliferating cells. The cultures were grown on 2% gelatin-coated or 6% collagencoated tissue culture flasks, 35-mm dishes, or 12-mm-diameter filter supports (Millicell CM) in endothelial basal medium (Clonetics) supplemented with 5% fetal bovine serum (FBS) and a BulletKit of additional additives including (per 500 ml) human epidermal growth factor (0.5 ml), hydrocortisone (0.5 ml), gentamicin (0.5 ml), bovine pituitary extract (2.0 ml), 1ϫ fungizone, and 1ϫ penicillin-streptomycin (31) . Filters were bathed in medium on both sides of the filter until a monolayer formed that was tight to fluid for at least 12 h; monolayers formed after 4-6 days in culture. The endothelial cell primary cultures prepared are as follows: human umbilical vein endothelial cells (HUVEC), human umbilical artery endothelial cells (HUAEC), human coronary artery endothelial cells (HCAEC), human pulmonary artery endothelial cells (HPAEC), human aortic endothelial cells (HAEC), and human lung microvascular endothelial cells (HLMVEC) .
Bioluminescence detection of ATP released from endothelial cell cultures and monolayers. These methods and materials have been published previously (30) in detail for experiments on epithelial monolayers. Similar methods were followed for endothelial monolayers. Briefly, Opti-MEM-I medium (GIBCO-BRL) with 2 mg/ml luciferin-luciferase reagent (Calbiochem) was added to the apical or basolateral side of the monolayer or directly into a culture grown in 35-mm dishes. Basal levels of ATP release were measured for at least 2 min in 15-s, nonintegrated photon collection periods in a TD-20/20 Luminometer (Turner Designs). Distilled water with 2 mg/ml luciferin-luciferase was added to dilute the osmotic strength of the Opti-MEM, and luminescence was measured for at least 2 min as described above. 4,4Ј-Diisothiocyanostilbene-2,2Ј-disulfonic acid (DIDS) and NaCl were added acutely during these luminescence measurements, since they had no effect on luciferase enzyme activity (7, 30) . Apyrase or hexokinase was added at the end of the time courses to eliminate any ATP left in the medium. All assays were performed at room temperature unless otherwise specified. Specifics on data analysis and statistics have been published previously (30) or are described in figure and table legends.
Some important additional points must be emphasized that were not pointed out in our original paper on this assay (30) . Different batches of luciferin-luciferase reagent were needed to complete these studies, giving rise to some differences in luminescence detection (for example, see Table 1 vs.  Table 2 ). Unfortunately, we could not perform an ATP standard curve on every vial of detection reagent because we would have run out of detection reagent for the actual ATP release studies on endothelial cell monolayers. We also did not inhibit ecto-ATPases in any pharmacological way in these assays (besides cooling of the monolayers). It also is important to note that the medium used in the release detection assay included 140 mM chloride and that chloride inhibits luciferase activity. As such, together with ectoATPase activity uninhibited and luciferase inhibited by physiological amounts of extracellular chloride, we may be underestimating ATP levels in the extracellular milieu. Therefore, luciferase acts as an "ATP sensor" in this bioassay, not a consumer of ATP.
Degenerate P2X receptor RT-PCR. Endothelial primary cultures were grown to confluence on collagen-coated flasks, and total RNA was extracted with Trizol reagent (Life Technologies). Total RNA was treated with DNase and reverse transcribed by standard methods. Each PCR reaction contained 1 M dNTP mix, 2 M forward primer, 2 M reverse primer, 0.5 l Taq polymerase (Perkin-Elmer), 10ϫ PCR buffer (1.5 mM MgCl2), and cDNA template. The PCR cycle began with a 5-min, 94°C "hot start" and was followed by 40 cycles of 30 s at 94°C, 60 s at 52°C, and 60 s at 72°C. A 10-min, 72°C elongation ended the reaction. PCR products were run on a 1.5% agarose gel beside a 100 base pair (bp) DNA ladder. Primers were as follows: ␤-actin forward primer, 5Ј-TGA CGG GGT CAC CCA CAC TGT GCC CAT  CTA-3Ј; ␤-actin reverse primer, 5Ј-CTA GAA GCA TTG CGG  TGG ACG ATG GAG GG-3Ј; P2XR degenerate forward  primer, 5Ј-TTC ACC MTY YTC ATC AAR AAC AGC ATC-3Ј;  and P2XR degenerate reverse primer, 5Ј-TGG CAA AYC  TGA AGT TGW AGC C-3Ј. PCR products were rescued from agarose gel slices using the Qiaquick gel extraction kit (Qiagen). The purified PCR product was ligated into the pGEM-T vector (Promega). The ligations were transformed into JM109 competent cells (Promega), and the cells were plated onto Luria broth (LB) agar plates containing ampicillin (100 m/ml), X-Gal (40 l/ml), and isopropyl ␤-D-thiogalactopyranoside (100 g/ml). White colonies (those with ampicillin resistance and an interrupted ␤-galactosidase gene) were picked and grown in 6 ml of LB-ampicillin. The plasmids were isolated from the bacteria using a PerfectPrep miniprep kit (5 Prime-3 Prime). The purified DNA was denatured in 0.2 N NaOH and precipitated in 7.5 M NH 4Cl and 100% ethanol. The Sequenase dideoxy termination method (Amersham) with ␣-35 S-labeled dATP (NEN-Dupont) was used to sequence the purified DNA product. The DNA sequence was read and screened with the BLAST algorithm to determine the identity of the PCR product (1) . In this and other studies on epithelial cells, sequences for every P2XR subtype were amplified with the exception of P2X6, a brain-specific subtype (data not shown).
Immunoblotting with P2X receptor channel subtype-specific antibodies. Cells were lysed in a buffer containing 10 mM Tris, 0.5 mM NaCl, 0.5% Triton X-100, 50 g/ml aprotinin (Sigma, St. Louis, MO), 100 g/ml leupeptin (Sigma), and 100 g/ml pepstatin A (Sigma) adjusted to pH 7.2-7.4. Protein (20 g/lane) was run and separated on an 8% SDS polyacrylamide gel and then transferred to polyvinylidene difluoride membrane (Osmonics, Westborough, MA). Immunoblotting was performed with rabbit polyclonal antibody to P2X1, P2X2, P2X4, and P2X7 at a dilution of 1:500 (Alomone Laboratories, Jerusalem, Israel) or with antibody to P2X5 at a dilution of 1:1,000 (generous gift of Drs. Mark Voigt and Terry Egan, St. Louis University, St. Louis, MO). Reactivity was detected by horseradish peroxidase-labeled goat antirabbit secondary antibody (1:3,000 dilution) (New England BioLabs, Beverly, MA). Enhanced chemiluminescence was used to visualize the secondary antibody.
Fura 2-AM imaging of intracellular Ca 2ϩ . Cytosolic intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) in human vascular endothelial cells was measured with dual-excitation wavelength fluorescence microscopy (Deltascan, Photon Technologies, Princeton, NJ) using the permeant form of the fluorescent probe, fura 2-AM (Teflabs, Austin, TX). Fura 2 fluorescence was measured at an emission wavelength of 510 nm in response to excitation wavelengths of 340 and 380 nm, alternated at a rate of 25 Hz by a computer-controlled chopper assembly. Autofluorescence-corrected ratios (340 nm/380 nm) were calculated at a rate of 5 points/s using PTI software. Cells were grown on collagen-coated coverslips (1:30 dilution of Vitrogen 100 in PBS) cut to fit the circulating cuvette and were incubated in media containing 5 M fura 2-AM and 1 mg/ml Pluronic F-127 dissolved in dimethyl sulfoxide (DMSO) for 2 h to allow loading of the dye into the cells. After loading, a coverslip was rinsed in Ringer solution to remove extracellular fura 2-AM and was positioned in the cuvette at a 45°angle from the excitation light. Two glass capillary tubes were inserted into the cuvette. One of these tubes was extended to the bottom of the cuvette and connected by way of polyethylene tubing to an infusion pump. The other capillary tube was positioned at the top of the cuvette and served to remove fluid from the cuvette. Flow rate through the cuvette was ϳ5 ml/min. A Ringer solution was used containing (in mM) 148 NaCl, Materials. All chemicals were obtained from Sigma unless otherwise noted.
RESULTS

Endothelial cells in primary culture form resistive monolayers in vitro.
Human vascular endothelial cells were grown on 12-mm-diameter Millicell PC permeable filter supports to establish endothelial monolayers. This maneuver was necessary to study the sidedness of ATP release (see data below). Routinely, within 4-7 days, the endothelial monolayers were tight to fluid for a minimum of 1 h, which was significantly longer than the duration of the ATP release assays. For the HUVEC endothelial monolayers, transendothelial resistance (R TEndo ) was measured with a Voltohmeter. R TEndo was measured 2 days after seeding of the filters.
After only 2 days, R TEndo was 154 Ϯ 2 ⍀ ⅐ cm 2 (n ϭ 48 2 ; n ϭ 48), and monolayers were used for ATP release assays on days [5] [6] [7] . These data show that human vascular endothelial cells grown in primary cultures under these conditions formed endothelial monolayers.
ATP is released predominantly across the apical membrane of human endothelial cell monolayers. Bioluminescence detection of ATP released from human endothelial cells grown in primary culture as monolayers on permeable supports was performed to assess the magnitude and polarity of ATP release. Primary endothelial cell cultures from six different blood vessel preparations were compared. Significant apically directed ATP release was detected from all endothelial monolayers under basal conditions ( Fig. 1) . In sharp contrast, little ATP release was measurable in the basolateral medium under basal conditions, although these values were above background ( Fig. 1 ). Although this is a microassay that estimates ATP release from monolayers, correlation of luminescence values with a standard curve of [ATP] indicated that apically directed ATP release elaborated nanomolar quantities of ATP, whereas basolaterally directed ATP release produced only picomolar quantities (Table 1 ). In particular, HUVEC and HPAEC monolayers released the most ATP across the apical membrane, whereas lesser amounts were measured in the endothelial monolayers derived from other blood vessel sources. Table 1 also shows that luciferase is present in sufficient quantity in the assay to "sense" extracellular ATP but not to consume it rapidly over time. However, because this is a microassay and because ecto-ATPases compete with luciferase for the released ATP (see Fig. 6 ), the amount of released ATP being detected was likely underestimated. Nevertheless, a second y-axis (to the right of each luminescence data plot) shows absolute [ATP] calculated from the standard curve data provided in Table 1 . Together, these results show that endothelial cells release ATP under basal conditions constitutively and that this ATP release is directed predominantly across the apical membrane.
In one long-lived HUVEC primary culture, ATP release was measured across the apical membrane as a function of passage number (Fig. 2) . Apically directed ATP release under basal conditions was robust in early passages (Fig. 2) . However, by passages 9 and 10, the magnitude of ATP release waned (Fig. 2) . In contrast, basolaterally directed ATP release under basal conditions followed a Gaussian-like distribution (Fig. 2) . The peak value of basolaterally directed ATP release was measured at passage 8, whereas it was lower at earlier passages ( Fig. 2) . As in apically directed ATP release measurements, basolaterally directed ATP release waned at passages 9 and 10. This culture dedifferentiated at passage 11. All data from HUVEC primary cultures are included in Fig. 1 . These data show that ATP release was dependent on the age of primary culture. Because apically directed ATP release was much greater than basolateral ATP release, apically directed ATP release results are the focus of all subsequent discussion.
ATP release is potentiated by hypotonic challenge. Previous studies by our laboratory alone or in collaboration with other groups have shown that normal hepatocytes (13) , normal airway epithelial cells (7, 30) , and normal and cystic renal epithelia (34) release ATP profoundly under hypotonic conditions. Dilutions of the medium osmolality with increasing volumes of distilled water were compared with medium controls (similar added volumes of isotonic medium) in bioluminescence detection assays of ATP released from HUVEC monolayers. As little as 13% dilution stimulated a transient increase in ATP release, whereas more robust dilutions of the medium osmolality produced sustained increases in ATP release (Fig. 3) . Reconstitution of the medium osmolality by addition of a bolus of 50 mM NaCl (100 mosmol) reversed hypotonicity-induced ATP release across the apical membrane to levels measured under basal conditions (Fig. 3) . Further additions of NaCl, which made the medium hypertonic, inhibited basal ATP release in both water dilution and medium control experiments (Fig. 3) . In fact, addition of 150 mM NaCl (300 mosmol) inhibited apically directed ATP release under basal conditions by at least 75% (Fig. 3) . Note that significant volumes of isotonic medium added to the apical side of HUVEC monolayers had no effect on ATP release (Fig. 3) , showing that a dilution of osmolality and not a mechanical perturbation was stimulating ATP release across the apical membrane of HUVEC monolayers. Together, these re- Values provide a "ballpark" as to how luminescence relates to absolute [ATP] and the rate of appearance of ATP in the medium. Nanomolar amounts are being released constitutively that are upregulated to higher nanomolar amounts by agonists. This assay only underestimates what may be happening in vivo, because this is a microassay on a small filter (not a large dish or cells or a blood vessel) and because ecto-ATPases compete with luciferase for the released ATP (see Fig. 6 ). A spiked amount of ATP is cleared slowly over time by the luciferase reagent, showing that it is present in sufficient amount as a detection reagent that is an ATP sensor but does outcompete ecto-ATPases. The assay was designed to be a "real biology" assay in addition to being a real-time assay. Pharmacological inhibitors of ecto-ATPases also inhibit luciferase enzyme activity. ALU, arbitrary light units. sults show that hypotonicity potentiates ATP release across the apical membrane of HUVEC monolayers. Moreover, hypertonicity (addition of osmoles during isotonic medium controls) attenuates basal ATP release in medium controls (Fig. 3) .
Previously, we showed partial attenuation of ATP release in epithelial monolayers with the broad-specificity, mechanosensitive ion channel blocker GdCl 3 (7, 28, 30) . In HUVEC monolayers, GdCl 3 inhibited apically directed basal ATP release partially and in a dose-dependent manner (Fig. 4 , see legend for summarized data). In this study, we also discovered a second ATP release inhibitor, DIDS, a broad-specificity anion channel-blocking drug. Figure 4 also shows a representative time course illustrating complete block of basal ATP release with DIDS (see legend for summarized data). Similar blockade of hypotonicity-induced ATP release across the apical membrane was observed with GdCl 3 and DIDS (Fig. 4) . As in Fig. 3 , graded dilutions of the medium osmolality stimulated ATP release. GdCl 3 inhibited the potentiated ATP release partially, whereas DIDS inhibited ATP release fully ( Fig. 4 ; see legend for summarized data). Together, these data show that ATP release is inhibited by ion channelblocking drugs and suggest that an ATP-permeable conductive transport pathway may mediate ATP release across the apical membrane of endothelial cell monolayers.
ATP release is potentiated by the Ca 2ϩ agonists ionomycin and thapsigargin. Because agonists that increase cytosolic Ca 2ϩ have profound effects on endothelial cell function, signaling, and production and on release of vasoactive mediators such as nitric oxide (22, 24) , we examined the effect of Ca 2ϩ agonists on ATP release across the apical membrane of HUVEC monolayers. Ionomycin (2 M), a Ca 2ϩ ionophore that promotes Ca 2ϩ influx into the cell from extracellular stores, elicited an immediate increase in ATP release (Fig. 5) . Unlike the hypotonicity-induced ATP release phenotype where luminescence increased and remained elevated for a few minutes before decaying over time, ionomycin-induced ATP release was immediate and continued to increase over the 8-min exposure Fig. 3 . Hypotonic challenge stimulates ATP release across the apical membrane of HUVEC endothelial cell monolayers. Raw luminescence values for HUVEC monolayers exposed to hypotonic challenge (Hypo) or to equal volumes of isotonic medium (a similar amount of luciferin-luciferase reagent was present in all stages of the experiment; n ϭ 6 each). Reconstitution of medium osmolality with NaCl reversed hypotonicity-induced ATP release. Note that hyperosmolality in medium controlled and, after the third addition of 50 mM NaCl to water dilutions, inhibited basal ATP release to low levels. The y-axis at right shows a correlation with absolute [ATP] that is an approximation by correlation with the standard curve shown in Table 1 . Table 1. period (Fig. 5) . Addition of DIDS had little inhibitory effect on the ionomycin response, whereas addition of hexokinase rapidly abolished the luminescence signal (Fig. 5) . Thapsigargin (2 M), an inhibitor of the Ca 2ϩ -ATPase pump in organellar membranes that promotes a rise in cytosolic Ca 2ϩ by blocking uptake and sequestration of Ca 2ϩ in intracellular stores, triggers a slower rise in ATP release that peaked between 1 and 2 min following addition (Fig. 5) . This response decayed to basal values over the stimulation period, and the luminescence signal was abolished by hexokinase (Fig.  5 ). Chronic treatment with thapsigargin eventually lowers cytosolic Ca 2ϩ . The transient stimulation suggests that thapsigargin in the later phase of the stimulation was causing cytosolic Ca 2ϩ to fall, inhibiting ATP release. Interestingly, although DIDS inhibits basal ATP release in the absence of thapsigargin, DIDS had no effect on the luminescence signal in the presence of thapsigargin (Fig. 5) , suggesting that the DIDS-sensitive ATP release mechanism under basal conditions may require intracellular Ca 2ϩ . Importantly, pretreatment of endothelial monolayers with 1,2-bis(2-aminophenoxy)ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA)-AM (10 M, 30-to 60-min pretreatment), the permeable form of the Ca 2ϩ -chelating agent, abolished ionomycin-induced ATP release. In the absence of BAPTA-AM, ionomycin increased ATP release acutely from 6.79 Ϯ 1.36 to 21.82 Ϯ 3.99 arbitrary light units (ALU) [change (⌬): 15.03 Ϯ 2.64 ALU; n ϭ 5] within 15 s and to a sustained value 8 min after addition of 50.01 Ϯ 3.99 ALU (⌬38.79 Ϯ 1.90 ALU; n ϭ 5). In the presence of the Ca 2ϩ chelator, ionomycin failed to stimulate ATP release acutely (⌬1.40 Ϯ 0.80 ALU; n ϭ 5) and chronically (⌬2.02 Ϯ 0.76 ALU; n ϭ 5). Together, these data show that intracellular Ca 2ϩ regulates the release of ATP across the apical membrane of human endothelia and promotes extracellular ATP signaling in the endothelial microenvironment in vitro.
Temperature affects dynamics and magnitude of constitutive, hypotonicity-induced, and Ca 2ϩ agonist-stimulated ATP release assay: a role for exocytosis and ecto-ATPases. To address the possible role of exocytosis in the release of ATP via ATP-filled vesicles, we performed our standard ATP release assay in temperature-controlled rooms at 4, 25, 30, and 37°C. Fortunately, these temperatures do not affect the luciferase detection assay significantly ( Table 2 ). Incubation of cells or monolayers at 4°C slows vesicle trafficking along the secretory pathway, even preformed vesicles that are poised to fuse with the plasma membrane. Figure 6A shows that constitutive release was not affected in its magnitude by performing the experiment at 4°C vs. 25°C. In sharp contrast, however, ϳ40% of the Ca 2ϩ agonist-and hypotonicity-induced ATP release phenotype was abolished by reduced temperature incubation and assay, suggesting that exocytosis may play a partial role as a mechanism of ATP release.
To our surprise, assay temperatures higher than room temperature produced no increase in bioluminescence. At 37°C, we observed a reduced signal at all stages of the assay (Fig. 6B) . At the end of the first stage of the assay monitoring basal release, the 37°C signal was less than room temperature (Fig. 6B) . The Values are averaged ALU from 3 separate standard curves performed over the course of the fixed temperature assays. Standard error was Ͻ10% for all values at all concentrations of ATP. Table 1 .
Ca 2ϩ agonist-and hypotonicity-induced ATP release signal also was reduced at higher temperature (Fig.  6B) . Upon more careful review of the data, we found that the decay in bioluminescence in all stages of the experiment was most pronounced at 37°C. This is shown best when comparing basal or constitutive ATP release at 4°C vs. 37°C (Fig. 6C) ; completely different phenotypes are observed. A gradual rise in bioluminescence was observed at 4°C, suggesting that ectoATPases no longer compete for the released ATP. In sharp contrast, at 37°C, the signal peaked within 1 min and decayed by almost 50% by 6 min. In these assays, constitutive ATP release was measured for 6 min, followed by ionomycin-induced release for 8 min and hypotonicity-induced release for 6 min. Blockade with DIDS or GdCl 3 and hexokinase was then carried out. Together, these data show that ecto-ATPase activity, attenuated at 25°C and inhibited at 4°C, is maximally active at 37°C and competes successfully with luciferase for the released ATP. Moreover, the loss of signal at 37°C suggests that ecto-ATPase activity outcompetes luciferase, whereas the attenuated signal at 4°C for Ca 2ϩ agonist-and hypotonicity-induced ATP release suggests a component of ATP release that relies on exocytosis of ATP-filled vesicles.
P2X receptor channels are expressed by human endothelial cells. To test the hypothesis that subtypes of a subclass of purinergic receptors, the P2X receptor channels (P2XRs), are expressed in endothelial cells, we performed degenerate RT-PCR. To confirm the authenticity of the cDNA before P2XR RT-PCR, we performed RT-PCR with primers for the housekeeping gene ␤-actin (Fig. 7) . The same cDNA was amplified with primers designed from an alignment of the first three rat P2XR cDNA sequences (rP2XR 1-3) in a PCR reaction. Figure 7 shows bands of the expected size (330 bp) in all endothelial cell samples. Negative controls (no cDNA) lacked the 330-bp band (Fig. 7) . There are no bands in RNA samples amplified without pretreatment with reverse transcriptase (data not shown). As a positive control, amplification of the human P2Y 2 gene from HUVEC total RNA also was performed. A band of the expected size (483 bp) was amplified that was confirmed to be P2Y 2 (Fig. 7, inset) . Together, these results show that endothelial cells derived from multiple vascular beds express P2X receptor channels. Confirmatory results for a P2Y 2 G protein-coupled receptor also are shown.
Human endothelial cells express multiple P2X receptor channel isoforms. Although it is clear that endothelial cell primary cultures express P2X receptors, it is unclear from RT-PCR alone which P2XR isoforms are expressed. To determine which isotypes are present, Table 1. we performed a large-scale cloning and sequencing analysis. Multiple colonies containing pGEM-T plasmid with P2XR PCR insert were sequenced from each cell type in an effort to determine whether P2X receptor channel isoforms were expressed and which P2X receptor isotypes were expressed most abundantly. Sequences were subjected to BLASTN analysis (1) to determine which P2X receptor isoforms were present in each endothelial cell primary culture. Table 3 shows the results of this differential DNA sequencing analysis for the five endothelial cell primary cultures analyzed. Readily apparent from this analysis, P2X 4 and P2X 5 were present in all samples (Table 3 ). These two isoforms were the only isoforms found in HPAEC (Table 3). P2X 1 expression was unique to HCAEC, whereas P2X 7 was found only in HAEC and HCAEC (Table 3) . Novel sequences were found rarely in both primary cultures derived from umbilical vasculature in HAEC, HUAEC, and HUVEC (Table 3) . Interestingly, these novel sequences were most identical to splice variants or isolated regions of P2XRs. In these stretches of homology, sequence identity was virtually 100%, although this stretch only encompassed Ͻ50% of the PCR product. More work is being performed with these clones that is beyond the scope of this study; similar novel P2XR-like sequences have been identified in epithelial cell models from lung and liver (Taylor AL and Schwiebert EM, unpublished observations). HLMVEC P2X PCR products of the expected size were obtained but were not processed in DNA sequencing analysis. Figure 8 also shows representative sequences from the four identified subtypes. Together, these studies show that the P2X receptor channel isoforms P2X 4 and P2X 5 are expressed by human endothelial primary cultures derived from multiple vascular beds.
Abundant expression of P2X 4 and P2X 5 is confirmed by immunoblot analysis. To show definitively that P2X 4 and P2X 5 were expressed as membrane proteins, we performed immunoblotting of membrane protein lysates prepared from HUVEC monolayers. Western blot analysis revealed that nascent (unglycosylated) forms (ϳ40-50 kDa) as well as glycosylated forms (60-80 kDa) of P2X 4 receptor channel protein were found in HUVEC monolayers (Fig. 9) . For P2X 5 , a band corresponding to the expected size of the nascent form was prominent at ϳ40-50 kDa, whereas little, if any, glycosylated form was observed. In both P2X 4 and P2X 5 immunoblots, a higher molecular mass band of 120-140 kDa also was detected. Each of these bands Fig. 7 . P2X receptor channel mRNA is expressed in endothelial cells. A 330-bp PCR product is found in all endothelial cell samples. A product also was found in multiple other HUVEC samples and in HLMVEC samples (data not shown). ␤-Actin also was amplified to authenticate cDNA before purinergic receptor PCR. The G proteincoupled P2Y2 receptor gene also was amplified from 2 different HUVEC samples (see inset). Negative controls (NC) had no PCR product. Gels are representative of multiple amplifications. 100 bp L, 100-bp DNA ladder. Values are based on minipreps sequenced and subjected to BLASTN analysis. Human lung microvascular endothelial cell (HLMVEC) PCR products were not processed in this manner, although a band of the expected size was amplified from these primary cultures as well (data not shown). "Other" reflects sequences with partial homology to a portion of a P2X receptor subtype sequence that may be a novel type of P2X receptor channel or an orphan receptor channel. These primers detect each P2XR subtype; however, we have never detected P2X6, a brain-specific subtype, in any endothelial or epithelial mRNA sample to date (over 300 DNA sequences). HAEC, human aortic endothelial cells; HCAEC, human coronary endothelial cells; HPAEC, human pulmonary artery endothelial cell; HUAEC, human umbilical artery endothelial cells. could be competed away by the peptide immunogen used to generate the antibody (data not shown). No consistent signals were observed for P2X 1 , P2X 2 , or P2X 7 (data not shown). Together, these data show that P2X 4 and P2X 5 receptor channel subtypes are expressed as membrane proteins poised to receive extracellular ATP signals. These data agree with degenerate RT-PCR analysis showing abundant expression of the same two P2XR subtypes.
Nucleotide agonists increase cytosolic Ca 2ϩ in human vascular endothelial cells. In HAEC and HUVEC cells loaded with fura 2-AM, the effect of individual nucleotide agonists and cocktails of P2Y-and P2X-selective agonists on cytosolic Ca 2ϩ was assessed. As this fura 2 analysis was being performed in addition to the ATP release assays and receptor expression studies, Yamamoto et al. (35) Only a few sequence differences were found, and they are shown in boldface or as dashes (for a missing base pair). As shown in Table 1 , P2X4 and P2X5 sequences were common, whereas P2X1 and P2X7 sequences were rarely found in this degenerate analysis. Fig. 9 . P2X4 and P2X5 protein is found in membrane protein lysates from HUVEC endothelial cell primary cultures. A tight and clear band of the expected size (40-50 kDa) was found for the nascent polypeptide for both P2X4 and P2X5 (reflected by arrows). Higher molecular mass forms (especially for P2X4 at ϳ60-70 kDa) were found (indicated by asterisks). Slightly higher molecular mass forms are glycosylated forms of the P2X receptor channel (they are inhibited by tunicamycin and eliminated by PNGase F treatment; data not shown). The band Ͼ100 kDa (also competed away by block with peptide immunogen) may be an SDS-resistant P2XR aggregate. Rainbow markers were used in these blots; molecular mass was adjusted to account for dyed marker migration being at least 10 kDa slower than that of nondyed markers.
Basal [Ca 2ϩ ] i in endothelial cell primary cultures was 60 Ϯ 6 nM (n ϭ 9). Addition of a cocktail of P2Y receptor-selective agonists (UDP, ADP, and UTP; 100 M each) triggered an increase in [Ca 2ϩ ] i that had transient (⌬93 Ϯ 14 nM for peak responses; n ϭ 9) and sustained (⌬45 Ϯ 6 nM before washout; n ϭ 9) components. An example of data calibrated to calculate free [Ca 2ϩ ] i shows that the P2Y receptor agonist cocktail increased [Ca 2ϩ ] i , which showed only limited desensitization (Fig. 10A) . Similar addition of a cocktail of P2X receptor-selective agonists (benzoyl-benzoyl ATP and ␣,␤-methylene-ATP, 100 M each) failed to increase [Ca 2ϩ ] i (n ϭ 9; see Fig. 10A for example) . UDP (100 M) and ADP (100 M) produced weak transient responses (⌬30 Ϯ 5 nM) that were inconsistent from culture to culture, suggesting that weak expression of P2Y 4 , P2Y 6 , and/or P2Y 11 may be present in these cultures. Addition of UTP (100 M) elicited a response that mirrored the P2Y receptor cocktail response with transient (⌬55 Ϯ 9 nM for peak responses; n ϭ 4) and sustained (⌬30 Ϯ 5 nM before washout; n ϭ 4) components. An example of a UTP stimulation is shown in Fig. 10B . This trace in Fig. 10B shows the fluorescence ratio data for comparison with the calibrated data in Fig. 10 . P2 receptor agonists increase cytosolic Ca 2ϩ and ATP scavengers and receptor antagonists lower basal cytosolic Ca 2ϩ in HUVEC endothelial cell primary cultures. A: a cocktail of P2Y-selective agonists (UTP, ADP, and UDP, 100 M each) was added in 3 separate boluses to reproducibly increase cytosolic Ca 2ϩ . In sharp contrast, a cocktail of 2 P2X-selective agonists failed to increase Ca 2ϩ . Calibrated data for actual free cytosolic Ca 2ϩ is shown. B: in a separate experiment, the effect of UTP alone (100 M) is shown in a longer-lived time course. In this plot, fluorescence ratio of the dual-wavelength fura 2 dye is shown. C: in a third experiment plotting fluorescence ratio, a cocktail of ATP, ADP, and adenosine scavengers (designed to eliminate any and all active purinergic agonists that would be released endogenously into the system) lowered basal cytosolic Ca 2ϩ . Suramin, a P2 receptor antagonist, was without effect at the 1 M dose; however, 10 and 100 M doses reversibly lowered basal cytosolic Ca 2ϩ . This experiment was representative of 3 such time courses that produced similar results. All agonists, antagonists, and inhibitors were screened against all wavelengths that detect the fura 2-AM fluorescent dye to ensure that none affected fura 2 fluorescence. For example, pyridoxal phosphate 6-azophenyl-2Ј,4Ј-disulfonic acid tetrasodium (PPADS), another P2 receptor antagonist, is autofluorescent and cannot be used for these experiments. Fig. 10A . Addition of ATP (100 M) produced similar effects but with still lesser magnitude (⌬36 Ϯ 5 nM for peak responses and ⌬23 Ϯ 3 nM before washout; n ϭ 4). Together, our interpretation, from the panel of nucleotide agonists that probe P2Y vs. P2X receptors in a given cell type, is that P2Y receptors, most prominently P2Y 2 Figure 10C shows that a scavenger cocktail designed to eliminate ATP, ADP, AMP, and adenosine that included 0.1 U/ml hexokinase (converts ATP to ADP), 0.1 U/ml apyrase (converts ATP and ADP to AMP), and adenosine deaminase (converts adenosine to inert inosine) lowered basal Ca 2ϩ significantly and in a manner that was reversible with a wash. Moreover, in the same experiment, suramin, an antagonist that blocks P2Y and P2X receptor subtypes, lowered basal cytosolic Ca 2ϩ in a dose-dependent and reversible manner. Together with findings for exogenous nucleotide agonists delivered to the fura 2-loaded endothelial cells, these data suggest that endogenous ATP, released into the circulating imaging system, is sufficient in amount to maintain basal cytosolic Ca 2ϩ levels in an autocrine/paracrine manner.
DISCUSSION
The strength of this study is the integrative analysis of all limbs (release, receptors, and receptor-driven signaling) of autocrine purinergic signaling. These studies were performed on several different human endothelial cell primary cultures grown as monolayers. To our knowledge, there are several novel aspects of the study. First, we have performed real-time bioluminescence detection of released ATP on endothelial monolayers. Burnstock's group has documented ATPstimulated ATP release, lipopolysaccharide (LPS)-driven ATP release, and shear stress-induced ATP release from HUVEC primary cultures (5, 6, 36) . However, these were nonpolarized cultures, whereas our studies were performed on human primary endothelial cell monolayers. Second, we have assessed the sidedness of ATP release from endothelial monolayers. Third, systematic analysis of constitutive, Ca 2ϩ agonist-induced, and hypotonicity-induced ATP release as well as the temperature dependence of basal and stimulated ATP release has not all been performed in this integrative way. Fourth, through the use of ion transport inhibitors such as DIDS or GdCl 3 and inhibition of exocytosis with 4°C cooling, we have uncovered roles for transport and exocytosis in ATP release from biological cells. Similar data have been shown in epithelial and heterologous cells (7, 13, 28, 30, 34) . Although the blockade with DIDS, Gd 3ϩ , and NaCl is rapid, ATP standard curves in the absence and presence of these substances do not affect luciferase activity (7) . We cannot rule out the fact that they might somehow speed the buffering capacity of the cell or enhance ecto-ATPase activity; however, the fact that DIDS or Gd 3ϩ (data not shown) was ineffective in blocking Ca 2ϩ agonist-induced ATP release suggests a different cellular mechanism. Moreover, the fact that we were dealing with a Cl Ϫ -containing medium in all stages of the experiment shows that we were dealing with a luciferase that has very different biochemical properties from that of a luciferase lyophilized and prepared in Cl Ϫ -free solutions. Thus reversal of hypotonicityinduced ATP release with NaCl suggests an osmotic mechanism. Fifth, along with extensive documentation of P2Y receptor expression on endothelial cells, we have provided degenerate RT-PCR and biochemical evidence for expression of multiple P2X receptors (P2X 4 and P2X 5 ) as well as P2Y 2 in positive controls. These data, together with the effect of ATP scavengers and ATP receptor antagonists on basal Ca 2ϩ , suggest that an autocrine and paracrine signaling loop exists in the circulation. Sixth, we have provided new evidence that P2X receptors may not mediate Ca 2ϩ influx directly but, rather, may stimulate voltage-dependent Ca 2ϩ channels through changing membrane potential. At the center of this system, endothelial cells are a rich source of released ATP under basal or stimulated conditions. Because endothelial cells also express multiple purinergic receptors, endothelial cells could undergo autocrine "self-regulation" or modulate the activity of neighboring cells (circulating cells, vascular smooth muscle cells) that also express P2X receptor channels and P2Y G protein-coupled receptors and could transduce this extracellular ATP signal.
How might ATP, in an autocrine or paracrine manner, affect vascular function? P2Y G protein-coupled receptors coupled to phospholipases stimulate signal transduction within most cells (21, 27) . Phospholipase C-␤ (PLC-␤) is the major signal transduction enzyme coupled to P2Y receptors (21); however, evidence also exists for coupling to PLD and PLA 2 in specific cell types such as Madin-Darby canine kidney renal epithelial cells (14) . As such, P2Y receptors trigger phosphoinositide signaling and increases in intracellular Ca 2ϩ . P2X receptor channels, either by themselves or by depolarizing the membrane to open voltage-gated Ca 2ϩ channels, may mediate capacitive Ca 2ϩ entry and signaling (8, 11) . Our work suggests that P2X receptor channels may not mediate Ca 2ϩ influx from extracellular stores, as was suggested by Yamamoto et al. (35) .
The work on Ca 2ϩ permeability has been performed exclusively in neurons, oocytes, and heterologous cells. Ca 2ϩ permeability through the P2X receptor channels in patch-clamp experiments does not suggest independently that P2XRs increase cytosolic Ca 2ϩ significantly. One also cannot rule out P2X receptor stimulation of other signal transduction pathways that are, as yet, undiscovered. One also cannot rule out the possibility that P2X receptor channels may depolarize the membrane potential in some cell systems to allow Ca 2ϩ entry through voltage-dependent Ca 2ϩ channels that are expressed concomitantly.
Adenosine, a metabolite of ATP, has been studied extensively in the coronary circulation and in other vascular beds (2, 12, 17) . Adenosine affects vascular tone and cardiac function (2, 12, 17) . It is tempting to speculate that much of the adenosine in the circulation is created via metabolism of ATP. Indeed, ectoapyrases and ecto-ATPases are expressed by endothelial cells to metabolize ATP (15, 36) . In our data in assays performed at 37°C, the ATP release signal was dampened or decayed rapidly over time. Our assay detected ATP released by an endothelial monolayer by using a sufficient quantity of luciferase-luciferin detection reagent in the medium to compete with ectoapyrases and ectoATPases. ATP was consumed within seconds in the assay; that is why sharp increases and decreases were observed when ATP release was potentiated and inhibited. However, ecto-ATPases compete for ATP in this assay, raising the possibility that circulating adenosine may be derived, at least in part, from released ATP.
How might extracellular purinergic signaling be important in vascular pathophysiology? Extracellular purinergic signaling plays a central role in platelet function at the clotting zone (20) . Extracellular nucleotides and nucleosides may be detrimental or therapeutic, respectively, in ischemia-reperfusion injury (2, 10, 12, 17, 18, 25, 26) . Indeed, anoxia or ischemia of cardiac tissue may cause cell swelling that would, in turn, augment ATP release. Extracellular purinergic signaling by ATP and adenosine has been hypothesized to play a central role in modulation of skeletal muscle and renal blood flow and glomerular filtration rate in the kidney (19) . Recent evidence also has suggested that "cross talk" may exist between purinergic signaling and nitric oxide signaling in vascular beds (22, 24, 29) . These issues require further investigation. It is possible that inhibitors of ATP release, ATP scavengers, and/or purinergic receptor antagonists may be of benefit in hypertension or other circulatory syndromes and treatments.
In conclusion, these data initiate a new extracellular autocrine and paracrine signaling cascade that may have profound implications for vascular physiology and pathophysiology. The mechanisms of ATP release, the regulation of ATP release, purinergic receptor signaling, and their physiological roles in endothelial cell biology are future considerations.
